Researchers have discovered a common vulnerability in E. coli, Shigella, and other dangerous diarrhea-causing bacteria — enzymes they use to break through the gut's protective mucus layer. Antibodies targeting this shared region can neutralize all three pathogens, paving the way for a single combination vaccine. The findings, published in PNAS, could be a major breakthrough for a disease that kills millions globally each year.
Scientists at Washington University School of Medicine in St. Louis have identified what they're calling an "Achilles' heel" shared by some of the world's most dangerous gut bacteria — including enterotoxigenic E. coli (ETEC) and Shigella. These pathogens rely on three closely related enzymes (EatA, SepA, and Pic) to slice through the intestinal mucus barrier and establish infection. Block those enzymes, and you stop the bacteria before they ever cause disease.
Using patient samples and cryo-electron microscopy, the team found that antibodies targeting a common region of these enzymes could neutralize all three pathogens at once. Crucially, people who naturally developed these antibodies after ETEC infection — including children in Bangladesh — were less likely to get sick, providing real-world validation of the approach.
Key Takeaways:
Why it matters: Diarrheal disease is a top killer of young children worldwide, and the lack of vaccines against ETEC and Shigella has been a long-standing gap in global health. This discovery offers a concrete, scientifically validated target for vaccine developers — and a real shot at protecting millions.
